The global glucagon-like peptide-1 (GLP-1) agonists market was valued at USD 19.70 Billion in 2024, driven by the rising prevalence of type 2 diabetes and obesity across the globe. The market is anticipated to grow at a CAGR of 10.20% during the forecast period of 2025-2034, with the values likely to reach USD 52.03 Billion by 2034.
Base Year
Historical Year
Forecast Year
It is reported that the number of adults with diabetes worldwide has exceeded 800 million. The increasing prevalence of diabetes is expected to augment market demand for GLP-1 agonists as effective treatment solutions.
Amylyx Pharmaceuticals initiated the Phase 3 LUCIDITY trial for avexitide (a GLP-1 receptor antagonist) targeting post-bariatric hypoglycemia, with patient recruitment beginning in February 2025. The expanding use of GLP-1 receptor modulation beyond diabetes and obesity is projected to elevate the glucagon-like peptide-1 (GLP-1) agonists market value.
In December 2024, the FDA approved a generic once-daily injectable version of the GLP-1 receptor agonist liraglutide for managing blood sugar levels in type 2 diabetes patients aged over 10 years. The rise in regulatory approvals for generics and novel GLP-1 agonists is poised to boost market growth.
GLP-1 receptor agonists are widely used for type 2 diabetes and obesity treatment. These drugs mimic the GLP-1 hormone, thereby helping in the regulation of blood sugar, reducing appetite, and promoting weight loss. GLP-1 therapies offer dual benefits in diabetes and weight management and thus are becoming a preferred treatment option. Increased investment from pharma companies to expand GLP-1 production is a key market trend. Moreover, factors such as growing insurance coverage for GLP-1-based weight-loss treatments and a shift towards long-acting and oral GLP-1 drugs, are anticipated to positively impact the market dynamics in the coming years.
Rising Prevalence of Diabetes to Boost the Market Growth
The number of adults affected by diabetes across the globe was reported to exceed 800 million, increasing more than fourfold since 1990, as per the recent data released by The Lancet on World Diabetes Day. The rising diabetes burden is driving the market demand for GLP-1 receptor agonists. Moreover, the rising regulatory approvals and healthcare investments are also supporting the market expansion.
The market is witnessing several trends and developments to improve the current scenario. Some of the notable trends are as follows:
The market report offers a detailed analysis of the market based on the following segments:
Market Breakup by Drugs
Market Breakup by Application
Market Breakup by Route of Administration
Market Breakup by End User
Market Breakup by Distribution Channel
Market Breakup by Region
Segmentation Based on Drugs to Witness Substantial Growth
Based on the drugs, the market is segmented into dulaglutide, exenatide, liraglutide, tirzepatide, lixisenatide, and semaglutide. The semaglutide segment covers a significant market share owing to its high efficacy, availability of multiple formulations (injectable and oral), and widespread adoption for both diabetes and obesity treatment. Moreover, the growing demand for this segment across North America, Europe, and Asia-Pacific, coupled with rising insurance coverage and regulatory approvals, is anticipated to aid its expansion in the forecast period.
The market is divided into regions such as North America, Europe, Asia Pacific, Latin America, and Middle East and Africa. North America holds a substantial share of the market owing to the high prevalence of obesity and diabetes, robust healthcare infrastructure, and widespread GLP-1 drug adoption. Moreover, major pharmaceutical companies in the region are focused on developing next-generation GLP-1 drugs, including oral formulations and multi-receptor agonists, which are likely to expedite the market growth in the region.
The key features of the market report comprise patent analysis, grants analysis, funding and investment analysis, and strategic initiatives by the leading players. The major companies in the market are as follows:
Eli Lilly is a major player in the market, primarily due to its popular drug Mounjaro® (tirzepatide), which is approved for type 2 diabetes. The company is also working on next-generation dual and triple agonists (GLP-1, GIP, and glucagon receptor modulators) to improve metabolic health outcomes.
Sanofi S.A., a French multinational pharmaceutical and healthcare company, is focusing on expanding its metabolic disease pipeline and forming strategic partnerships to strengthen its position in the competitive GLP-1 space. With strong expertise in diabetes care, Sanofi is expected to significantly contribute to the glucagon-like peptide-1 (GLP-1) agonists market expansion.
Novo Nordisk covers a significant market share with semaglutide-based therapies such as Ozempic (for type 2 diabetes), Wegovy (for obesity), and Rybelsus (oral GLP-1 for diabetes). The company has successfully expanded its manufacturing facilities to meet growing demand and is actively working on longer-acting GLP-1 formulations and GLP-1 combination therapies to improve patient outcomes.
AstraZeneca, a British-Swedish multinational pharmaceutical and biotechnology company, is focusing on developing next-generation metabolic treatments that could complement GLP-1 therapies. The company has a strong presence in diabetes and cardiovascular drug development, working on combination therapies that may integrate GLP-1 receptor agonists with other metabolic drugs.
*Please note that this is only a partial list; the complete list of key players is available in the full report. Additionally, the list of key players can be customized to better suit your needs.*
Other key players in the market include Pfizer Inc., Boehringer Ingelheim, F. Hoffmann-La Roche, Amgen Inc., and GlaxoSmithKline plc.
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
| REPORT FEATURES | DETAILS |
| Base Year | 2024 |
| Historical Period | 2018-2024 |
| Forecast Period | 2025-2034 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Drugs |
|
| Breakup by Application |
|
| Breakup by Route of Administration |
|
| Breakup by End User |
|
| Breakup by Distribution Channel |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
Datasheet
One User
USD 3,299
USD 2,969
tax inclusive*
Single User License
One User
USD 5,499
USD 4,949
tax inclusive*
Five User License
Five User
USD 6,999
USD 5,949
tax inclusive*
Corporate License
Unlimited Users
USD 8,199
USD 6,969
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-723-689-1189
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City,1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
United States
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
United States (Head Office)
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-723-689-1189
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City, 1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
Share